Medical Oncology

, Volume 28, Issue 1, pp 315–321 | Cite as

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

  • Shu-zhen Wei
  • Ping Zhan
  • Mei-qi Shi
  • Yi Shi
  • Qian Qian
  • Li-ke Yu
  • Yong Song
Original Paper

Abstract

The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43–3.33; P = 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92–1.91; P = 0.13) and 1.02 (95% CI, 0.72–1.45; P = 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.

Keywords

ERCC1 XPD Polymorphism Predictive value NSCLC Platinum-based chemotherapy Meta-analysis 

References

  1. 1.
    Evans T. Chemotherapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med. 2005;26:304–13. doi:10.1055/s-2005-871989.PubMedCrossRefGoogle Scholar
  2. 2.
    Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62:4899–902.PubMedGoogle Scholar
  3. 3.
    Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Chen J, Larochelle S, Li X, et al. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature. 2003;424:228–32. doi:10.1038/nature01746.PubMedCrossRefGoogle Scholar
  5. 5.
    Rosell R, Taron M, Ariza A, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol. 2004;31:20–7. doi:10.1053/j.seminoncol.2003.12.011.PubMedCrossRefGoogle Scholar
  6. 6.
    Gazdar AF. DNA repair and survival in lung cancer—the two faces of Janus. N Engl J Med. 2007;356:771–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294–300. doi:10.1038/nm1491.PubMedCrossRefGoogle Scholar
  8. 8.
    Mantel NH. Statistical aspect of the analysis of data from retrospective studies of disease. Natl Cancer Inst. 1959;22:719–48. doi:10.1016/0021-9681(79)90031-6.Google Scholar
  9. 9.
    Zhou C, Ren S, Zhou S, et al. Genotyping single-nucleotide polymorphisms (SNPs) in ERCC1 and XRCC3 genes for efficacy prediction in chemotherapy of non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26.Google Scholar
  10. 10.
    Camps C, Sarries C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2003;4:237–41. doi:10.3816/CLC.2003.n.004.PubMedCrossRefGoogle Scholar
  11. 11.
    Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15:1194–203. doi:10.1093/annonc/mdh319.PubMedCrossRefGoogle Scholar
  12. 12.
    Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004;44:311–6. doi:10.1016/j.lungcan.2003.11.019.PubMedCrossRefGoogle Scholar
  13. 13.
    Yuan P, Miao XP, Zhang XM, et al. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2006;28:196–9.PubMedGoogle Scholar
  14. 14.
    Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 2006;106:2421–7. doi:10.1002/cncr.21885.PubMedCrossRefGoogle Scholar
  15. 15.
    Song DG, Liu J, Wang JH, et al. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Chin J Gerontol. 2007;1684-86.Google Scholar
  16. 16.
    Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56:281–8. doi:10.1016/j.lungcan.2006.12.002.PubMedCrossRefGoogle Scholar
  17. 17.
    Fan H, Jin GF, Shen HB. Relationship of XRCC1 and XPD gene polymorphisms with chemosensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. Pract Geriatr. 2008;22:306–14.Google Scholar
  18. 18.
    Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14:1797–803. doi:10.1158/1078-0432.CCR-07-1364.PubMedCrossRefGoogle Scholar
  19. 19.
    Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10:118–23. doi:10.3816/CLC.2009.n.015.PubMedCrossRefGoogle Scholar
  20. 20.
    Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27:3540–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Lenz HJ. The use and development of germline polymorphisms in clinical oncology. J Clin Oncol. 2004;22:2519–21. doi:10.1200/JCO.2004.04.900.PubMedCrossRefGoogle Scholar
  22. 22.
    Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 2008;24:331–44.CrossRefGoogle Scholar
  23. 23.
    Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMedGoogle Scholar
  24. 24.
    Yu JJ, Mu C, Lee KB, Okamoto A, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res. 2007; 382:13–20. doi:10.1016/S1383-5726(97)00004-6.Google Scholar
  25. 25.
    Evans E, Moggs JG, Hwang JR, et al. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 1997;16:6559–73. doi:10.1093/emboj/16.21.6559.PubMedCrossRefGoogle Scholar
  26. 26.
    Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007;4:59–71.PubMedGoogle Scholar
  27. 27.
    Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22:2594–601. doi:10.1200/JCO.2004.08.067.PubMedCrossRefGoogle Scholar
  28. 28.
    Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst. 2000;92:440–1.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Shu-zhen Wei
    • 1
  • Ping Zhan
    • 2
  • Mei-qi Shi
    • 3
  • Yi Shi
    • 1
  • Qian Qian
    • 1
  • Li-ke Yu
    • 2
  • Yong Song
    • 1
  1. 1.Department of Respiratory Medicine, Jinling HospitalNanjing University School of MedicineNanjingChina
  2. 2.Department of Respiratory MedicineNanjing Chest HospitalNanjingChina
  3. 3.Department of OncologyJiangsu Cancer Hospital Affiliated to Nanjing Medical UniversityNanjingChina

Personalised recommendations